Resveratrol Arrests and Regresses the Development of Pressure Overload- but Not Volume Overload-Induced Cardiac Hypertrophy in Rats

Abstract

Cardiac hypertrophy is a compensatory enlargement of the heart due to either volume overload (VO) and/or pressure overload (PO) that develops into heart failure if left untreated. The polyphenol resveratrol has been reported to regress PO-induced cardiac hypertrophy in rats. Our aim in this study was to assess the effectiveness of resveratrol on VO-induced cardiac hypertrophy. Sprague Dawley rats were subjected to aortocaval shunt and abdominal aortic banding surgeries to create VO and PO, respectively; sham-operated rats served as controls. To arrest the development of cardiac hypertrophy, daily resveratrol treatment (2.5 mg/kg body weight) was started 2 d postsurgery for 26 d and assessed by echocardiography at 2, 14, and 28 d postsurgery. Similarly, to regress cardiac hypertrophy resveratrol treatment was started after structural and functional abnormalities developed (14 d postsurgery) for 14 d and assessed by echocardiography at 14 and 28 d postsurgery. VO surgeries induced eccentric hypertrophy characterized by increased left ventricle internal dimensions (LVID) without wall thickening. Conversely, PO induced concentric hypertrophy with increased wall thickness without change in LVID. Lipid peroxidation, a marker for oxidative stress, was significantly elevated in both PO and VO rats. Resveratrol treatment arrested the development and regressed abnormalities in cardiac structure and function in PO but not VO rats. Treatment with resveratrol also significantly reduced oxidative stress in cardiac tissue of PO and VO rats. The results on cardiac structure and function demonstrate a potential for resveratrol in the treatment of cardiac hypertrophy due to PO but not VO.

Puerarin prevents cardiac hypertrophy induced by pressure overload through activation of autophagy

“…The results of the present study are summarized as follows: (1) puerarin could attenuate the progress of cardiac hypertrophy and inhibit cardiomyocyte apoptosis; (2) the protective effects of puerarin against cardiac hypertrophy and apoptosis might be exerted partly through restoration of autophagy, and (3) regulation of AMPK/mTOR signaling might be involved in this puerarininduced activation of autophagy.…”

“…During the early period of cardiac hypertrophy, a shift to raised ventricular tension in response to increased neurohumoral activation and hemodynamic load, which is characterized by increased protein synthesis and hypertrophic sarcomere, is the main compensatory mechanism [1,2]. However, if the stressors are sustained, the hypertrophic cardiomyocytes progressively die, ultimately leading to heart failure.…”

Effects of Pyrroloquinoline Quinone and Vitamin C on Diabetes Associated Testicular Dysfunction and Oxidative Damages in Testis of Streptozotocin-Induced Diabetic Mice: Histopathological Study

“…Both in vivo and in vitro studies suggest that PQQ can protect against several types of oxidative damages and irradiation injury [22,23]. Further, PQQ is found to be involved in regulating various physiological processes through its redox cycling property [16,[24][25][26]. In fact, PQQ is believed to possess potent antioxidant activity, much stronger than other quinones and enediols including ascorbic acid [27].…”

The effect of resveratrol on angiotensin II levels and the rate of transcription of its receptors in the rat cardiac hypertrophy model

“…The anti-hypertrophic effects of resveratrol have been reported in previous studies. Wojciechowski et al reported that treatment with resveratrol interrupts the progression and returning of structural disturbances and cardiac function in pressure overload and volume overload rats [31]. Another pretreatment of rats with resveratrol for 14 days protected the hearts against harmful cardiac hypertrophy [32].…”